Thomas Neumann is President & CEO of Nortis, a company commercializing organ-on-chip in vitro models that recapitulate tissue and organ microenvironments for studying human diseases and the effects of drugs and toxins. Dr. Neumann began his research on 3-D tissue models as a medical student at the University of Halle, Germany, where he received his MD summa cum laude in 2000. He continued his work in bioengineering at the University of Washington, inventing techniques for generating skeletal muscle and microvasculature in vitro. At VisionGate, Inc. he directed the development of cancer-diagnostic applications for the company’s microfluidic imaging platform. In 2007, he co-founded Nortis, Inc. as one of the first companies in the emerging organ-on-chip field. Dr. Neumann led Nortis’s participation in the five-year NIH/NCATS organ-on-chip Microphysiological Systems program. He is a frequent speaker at 3-D tissue model conferences and workshops.